Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Should You Buy Biogen Before a Big July Decision?
05:30am, Sunday, 19'th Mar 2023
Biogen's blockbuster drugs are losing exclusivity -- and that's weighing on earnings. The company now is counting on its latest Alzheimer's drug to turn things around.
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
09:56am, Thursday, 16'th Mar 2023
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive
1 Reason to Buy Biogen Stock, and 1 Reason to Sell
10:23am, Tuesday, 14'th Mar 2023
Biogen recently won U.S. approval for an important Alzheimer's disease therapy. However, this medicine still faces some concerning headwinds in the market.
U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map
03:09am, Wednesday, 08'th Mar 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.
Biogen Should Resume Strong Growth With Zuranolone Approval
02:47am, Tuesday, 07'th Mar 2023
Biogen Q4 revenue was down 7% y/y. Zuranolone is a breakthrough depression therapy with an August 5, 2023, PDUFA date.
Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference Conference (Transcript)
04:30pm, Monday, 06'th Mar 2023
Biogen Inc. (NASDAQ:BIIB ) 43rd Annual Cowen Healthcare Conference Call March 6, 2023 9:50 AM ET Company Participants Christopher Viehbacher - Chief Executive Officer Conference Call Participants Phil
Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi
09:47am, Monday, 06'th Mar 2023
The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.
FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July
09:27am, Monday, 06'th Mar 2023
Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.
3 Biotech Stocks To Watch Ahead Of March 2023
03:44pm, Saturday, 25'th Feb 2023
Do you have these three biotech stocks on your watchlist right now?
How Are Biotech ETFs Reacting to Q4 Earnings Releases?
03:48pm, Tuesday, 21'st Feb 2023
The latest earnings from some of the big biotech players came in at mixed this reporting season.
Biogen shares fall on 4Q results but Canaccord analysts remain optimistic about Alzheimer's drug
02:56pm, Wednesday, 15'th Feb 2023
Biogen Inc (NASDAQ:BIIB) shares fell Wednesday after the company reported declining fourth-quarter sales and revealed that it expects that trend to continue in 2023. The company expects sales to dec
Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key Metrics
01:33pm, Wednesday, 15'th Feb 2023
Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall
Biogen Boss Turns Corner on Alzheimer's Miscues
01:16pm, Wednesday, 15'th Feb 2023
The biotech company needs to embark on new growth path as former Sanofi CEO Chris Viehbacher takes the helm.
Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up
12:03pm, Wednesday, 15'th Feb 2023
Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.
Biogen Inc. (BIIB) Q4 2022 Earnings Call Transcript
12:00pm, Wednesday, 15'th Feb 2023
Biogen Inc. (NASDAQ:BIIB ) Q4 2022 Results Conference Call February 15, 2023 8:00 AM ET Company Participants Mike Hencke - Head, Investor Relations Christopher Viehbacher - CEO Michael McDonnell - Chi
